Tore Bengtsson

This inventor holds 14 USPTO granted patents and 18 published patent applications, plus 1 CIPO patent and 6 EPO patents. Top assignees: Atrogi Ab, Sigrid Therapeutics Ab, Zipforce Ab. Active years: 2017-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tore Bengtsson. Retrieved from https://idiyas.com/inventor/tore-bengtsson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 14 (Patent Applications = 18)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 13)

EPO Patents = 6 (Patent Applications = 27)

Average Co-Inventor Count = 1.7

ph-index = 4

Forward Citations = 37(Granted Patents)

Company Filing History:

Sigrid Therapeutics Ab

Years Active: 2017-2025

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12492129 - Highly structured porous silica materials and biological uses thereof (2025-12-09),

2. 12378216 - Heteroaryl(heterocyclyl)methanol compounds useful in the treatment of hyperglycaemia (2025-08-05),

3. 12280023 - Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia (2025-04-21),

4. 12121612 - Porous silica material for use as a pharmaceutical or dietary active ingredient (2024-10-22),

5. 12036210 - Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia (2024-07-16),

6. 11793774 - Chiral beta-hydroxyethylamines and their use in the treatment of hyperglycemia (2023-10-24),

7. 11648216 - Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia (2023-05-16),

8. 11603164 - Electric friction drive device and electric drive system (2023-03-14),

9. 11427539 - Beta-hydroxy heterocyclic amines and their use in the treatment of hyperglycaemia (2022-08-30),

10. 10695294 - Porous silica material for use as a pharmaceutical or dietary active ingredient (2020-06-30),

11. 10288602 - Screening method, a kit, a method of treatment and a compound for use in a method of treatement (2019-05-14),

12. 9891212 - Screening method, a kit, a method of treatment and a compound for use in a method of treatment (2018-02-13),

13. 9784726 - Screening method, a kit, a method of treatment and a compound for use in a method of treatment (2017-10-10),

14. 9657348 - Method of screening compounds for the treatment of diabetes (2017-05-23),

Title: The Innovative Contributions of Tore Bengtsson

Introduction

Tore Bengtsson is a notable inventor based in Vaxholm, Sweden. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of hyperglycaemia. With a total of 13 patents to his name, Bengtsson's work has had a considerable impact on medical science.

Latest Patents

Among his latest patents are innovative compounds such as heteroaryl(heterocyclyl)methanol compounds, which are useful in the treatment of hyperglycaemia. These compounds are defined by specific formulas that provide a foundation for their pharmaceutical applications. Another significant patent involves fluorophenyl beta-hydroxyethylamines, which also serve as potential treatments for hyperglycaemia. These advancements highlight Bengtsson's commitment to addressing critical health issues.

Career Highlights

Throughout his career, Tore Bengtsson has worked with various companies, including Atrogi AB and Sigrid Therapeutics AB. His experience in these organizations has allowed him to develop and refine his innovative ideas, contributing to the advancement of medical treatments.

Collaborations

Bengtsson has collaborated with notable professionals in his field, including Benjamin Pelcman and Robert Csikasz. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise.

Conclusion

Tore Bengtsson's contributions to the field of pharmaceuticals through his patents and collaborations demonstrate his dedication to innovation and improving health outcomes. His work continues to influence the treatment of hyperglycaemia and showcases the importance of research and development in medicine.

Profile summary based on public USPTO records.